Citations

Clear

2303 citation(s) found for "Yu, Edward".

Is Obesity an Endocrine Problem? [ Abstract ]
Rynearson, Edward H.

Mayo Clinic

Proceedings of the Royal Society of Medicine | July 19, 2019 | Volume: 44 | Issue: 11 | Pages: 951-952

10.1177/003591575104401111 | PMID 19993787 Get It

Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn’s Disease
Steinhart, A. Hillary , Bressler, Brian , Khanna, Reena , Afif, Waqqas , Bitton, Alain , Borgaonkar, Mark , Chauhan, Usha, Halloran, Brendan P. , Jones, Jennifer , Kennedy, Erin , Meddings, Jonathan B., Plamondon, Sophie , Rosenfeld, Greg , Seow, Cynthia H. , Williams, Chadwick, Bernstein, Çharles N. , Panaccione, Remo , Marshall, John K. , Targownik, Laura E. , Leontiadis, Grigorios I. , Loftus, Edward V. , Moayyedi, Paul , Murthy, Sanjay K. , Schwartz, David A. , Bernstein, Charles Noah

Mayo Clinic

Journal of the Canadian Association of Gastroenterology | July 10, 2019 | Volume: 2 | Issue: 3 | Pages: e1-e34

10.1093/jcag/gwz019 | PMID 31294378 Get It

Abstract Background & Aims Crohn’s disease (CD) is a lifelong illness with substantial morbidity, although new therapies and treatment paradigms have been developed. We provide guidance for treatment of ambulatory patients with mild to severe active luminal CD. Methods We performed a systematic review to identify published studies of the management of CD. The quality of evidence and strength of recommendations were rated according to the Grading of Recommendation Assessment, Development and Evaluation (GRADE) approach. Statements were developed through an iterative online platform and then finalized and voted on by a group of specialists. Results The consensus includes 41 statements focused on 6 main drug classes: antibiotics, 5-aminosalicylate, corticosteroids, immunosuppressants, biologic therapies, and other therapies. The group suggested against the use of antibiotics or 5-aminosalicylate as induction or maintenance therapies. Corticosteroid therapies (including budesonide) can be used as induction, but not maintenance therapies. Among immunosuppressants, thiopurines should not be used for induction, but can be used for maintenance therapy for selected low-risk patients. Parenteral methotrexate was proposed for induction and maintenance therapy in patients with corticosteroid-dependent CD. Biologic agents, including tumor necrosis factor antagonists, vedolizumab, and ustekinumab, were recommended for patients failed by conventional induction therapies and as maintenance therapy. The consensus group was unable to clearly define the role of concomitant immunosuppressant therapies in initiation of treatment with a biologic agent. Conclusions Optimal management of CD requires careful patient assessment, acknowledgement of patient preferences, evidence-based use of existing therapies, and thorough assessment to define treatment success.
Brain Lewy-Type Synucleinopathy Density Is Associated with a Lower Prevalence of Atherosclerotic Cardiovascular Disease Risk Factors in Patients with Parkinson’s Disease
Driver‐Dunckley, Erika , Sue, Lucia I., Shill, Holly A. , Mehta, Shyamal H. , Belden, Christine M. , Zamrini, Edward , Davis, Kathryn, Beach, Thomas G. , Driver-Dunckley, Erika D., Zhang, Nan , Adler, Charles H. , Serrano, Geidy E.

Mayo Clinic

Journal of Parkinson’s Disease | July 5, 2019 | Volume: 9 | Issue: 3 | Pages: 543-552

10.3233/jpd-191610 | PMID 31282425 Get It

Background: Some epidemiology studies suggest that atherosclerotic cardiovascular disease (ASCVD) risk factors increase the risk of developing Parkinson’s disease (PD). However, conflicting data suggest lower rates of ASCVD in PD. Objective: The objective of this study is to determine, with data from a longitudinal clinicopathological study, whether ASCVD risk factors are associated with a PD diagnosis and/or increased brain or peripheral load of Lewy-type synucleinopathy (LTS). Methods: All subjects were followed to autopsy and neuropathological examination in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND). Multivariable regression models, including age, gender, and smoking history, were used to investigate the association of a PD diagnosis or brain or submandibular gland LTS load with ASCVD risk factors. Results: 150 subjects were included (PD n = 60, controls n = 90). Univariable comparisons and regression models showed a general trend to inverse associations. The multivariable odds ratio (OR) of brain LTS load for carotid artery disease was 0.93 (95% CI: 0.86 to 0.98; p = 0.02), for anticoagulant use 0.95 (95% CI: 0.90 to 0.99; p = 0.04) and for abnormal heart weight 0.96 (95% CI: 0.92 to 0.99; p = 0.01). Composite clinical and overall (clinical + pathology composite risk scores) composite risk scores were also significantly lower in the PD subjects ( p = 0.0164 and 0.0187, respectively). Submandibular gland LTS load was not significantly related to ASCVD conditions. Conclusions: This study shows associations of higher brain LTS with lower prevalence of both clinical and pathological indices of ASCVD in PD subjects versus age-similar controls. We suggest that this is due to α-synuclein pathology-induced sympathetic denervation in PD.
DNA-Dependent Protein Kinase Drives Prostate Cancer Progression through Transcriptional Regulation of the Wnt Signaling Pathway
Kothari, Vishal , Goodwin, Jonathan F., Zhao, Shuang G. , Chang, S. Laura , Evans, Joseph R. , Wilder-Romans, Kari , Gabbara, Kristina M., Dylgjeri, Emanuela , Sun, Grace Y., Tomlins, Scott A. , Mehra, Rohit , Hege, Kristen , Filvaroff, Ellen, Schaeffer, Edward M. , Karnes, R. Jeffrey , Quigley, David A. , Speers, Corey , Spratt, Daniel E. , Gilbert, Luke A. , Ashworth, Alan , Chinnaiyan, Arul M., Raj, Ganesh V. , Feng, Felix Y. , Speers, Corey , Spratt, Daniel E , Zhao, Shuang G , Drake, Justin M , Yin, Yi Ming , Chou, Jonathan , Rathkopf, Dana E , He, Housheng Hansen , Knudsen, Karen E.

Mayo Clinic

Clinical Cancer Research | July 2, 2019 | Volume: 25 | Issue: 18 | Pages: 5608-5622

10.1158/1078-0432.ccr-18-2387 | PMID 31266829 Get It

Abstract Purpose: Protein kinases are known to play a prominent role in oncogenic progression across multiple cancer subtypes, yet their role in prostate cancer progression remains underexplored. The purpose of this study was to identify kinases that drive prostate cancer progression. Experimental Design: To discover kinases that drive prostate cancer progression, we investigated the association between gene expression of all known kinases and long-term clinical outcomes in tumor samples from 545 patients with high-risk disease. We evaluated the impact of genetic and pharmacologic inhibition of the most significant kinase associated with metastatic progression in vitro and in vivo. Results: DNA-dependent protein kinase (DNAPK) was identified as the most significant kinase associated with metastatic progression in high-risk prostate cancer. Inhibition of DNAPK suppressed the growth of both AR-dependent and AR-independent prostate cancer cells. Gene set enrichment analysis nominated Wnt as the top pathway associated with DNAPK. We found that DNAPK interacts with the Wnt transcription factor LEF1 and is critical for LEF1-mediated transcription. Conclusions: Our data show that DNAPK drives prostate cancer progression through transcriptional regulation of Wnt signaling and is an attractive therapeutic target in aggressive prostate cancer.
Prognostic Score and Cytogenetic Risk Classification for Chronic Lymphocytic Leukemia Patients: Center for International Blood and Marrow Transplant Research Report
Ahn, Kwang Woo , Hu, Zhen‐Huan , Volpe, Virginia O. , Antin, Joseph H. , Sorror, Mohamed L. , Press, Oliver W. , Pidala, Joseph, Negrin, Robert S., Uberti, Joseph P., Agura, Edward, Nash, Richard A. , Mehta, Jayesh, Forman, Stephen J. , Langston, Amelia , Hale, Gregory A., Marks, David I. , Ganguly, Sid, Reshef, Ran , Hildebrandt, Gerhard , Inamoto, Yoshihiro , Cahn, Jean‐Yves, Solh, Melhem , Kharfan‐Dabaja, Mohamed A. , Saad, Ayman , Aljurf, Mahmoud , Schouten, Harry C. , Hill, Brian T. , Pawarode, Attaphol , Kindwall‐Keller, Tamila L. , Saba, Nakhle S. , Copelan, Edward A. , Nathan, Sunita , Beitinjaneh, Amer , Černý, Jan , Wirk, Baldeep , Olsson, Richard F. , Bashey, Asad, Sobecks, Ronald , Alyea, Edwin P. , Saber, Wael , Brown, Jennifer R. , Hogan, William, Kharfan-Dabaja, Mohamed A., Saad, Ayman , Press, Oliver , Olsson, Richard F , Reshef, Ran , Kim, Haesook T. , Davids, Matthew S. , Shadman, Mazyar , Hogan, William J. , Devine, Steven M. , McGuirk, Joseph P. , Giralt, Sergio , Perales, Miguel‐Angel , Battiwalla, Minoo , Gale, Robert Peter , Hamadani, Mehdi , Bacher, Ulrike , Lazarus, Hillard M. , Cahn, Jean‐Yves , Ghosh, Nilanjan , Savani, Bipin N. , Grunwald, Michael R. , Yared, Jean A. , Nishihori, Taiga , Chhabra, Saurabh , Gergis, Usama , Popat, Uday R , Sorror, Mohamed

Mayo Clinic

Clinical Cancer Research | June 28, 2019 | Volume: 25 | Issue: 16 | Pages: 5143-5155

10.1158/1078-0432.ccr-18-3988 | PMID 31253630 Get It

Abstract Purpose: To develop a prognostic model and cytogenetic risk classification for previously treated patients with chronic lymphocytic leukemia (CLL) undergoing reduced intensity conditioning (RIC) allogeneic hematopoietic cell transplantation (HCT). Experimental Design: We performed a retrospective analysis of outcomes of 606 patients with CLL who underwent RIC allogeneic HCT between 2008 and 2014 reported to the Center for International Blood and Marrow Transplant Research. Results: On the basis of multivariable models, disease status, comorbidity index, lymphocyte count, and white blood cell count at HCT were selected for the development of prognostic model. Using the prognostic score, we stratified patients into low-, intermediate-, high-, and very-high-risk [4-year progression-free survival (PFS) 58%, 42%, 33%, and 25%, respectively, P < 0.0001; 4-year overall survival (OS) 70%, 57%, 54%, and 38%, respectively, P < 0.0001]. We also evaluated karyotypic abnormalities together with del(17p) and found that del(17p) or ≥5 abnormalities showed inferior PFS. Using a multivariable model, we classified cytogenetic risk into low, intermediate, and high (P < 0.0001). When the prognostic score and cytogenetic risk were combined, patients with low prognostic score and low cytogenetic risk had prolonged PFS (61% at 4 years) and OS (75% at 4 years). Conclusions: In this large cohort of patients with previously treated CLL who underwent RIC HCT, we developed a robust prognostic scoring system of HCT outcomes and a novel cytogenetic-based risk stratification system. These prognostic models can be used for counseling patients, comparing data across studies, and providing a benchmark for future interventions. For future study, we will further validate these models for patients receiving targeted therapies prior to HCT.
Characteristics and Scope of Training of Clinicians Participating in the US Direct-to-Consumer Marketplace for Unproven Stem Cell Interventions
Fu, Wayne , Smith, Cambray , Turner, Leigh , Fojtik, Joseph, Pacyna, Joel E. , Fojtik, Joseph Edward , Master, Zubin

Mayo Clinic

JAMA | June 25, 2019 | Volume: 321 | Issue: 24 | Pages: 2463

10.1001/jama.2019.5837 | PMID 31237628 Get It

Mitochondrial dysfunction and cell senescence: deciphering a complex relationship
Chapman, James , Fielder, Edward , Passos, João F. , Passos, João F

Mayo Clinic

FEBS Letters | June 18, 2019 | Volume: 593 | Issue: 13 | Pages: 1566-1579

10.1002/1873-3468.13498 | PMID 31211858 Get It

Cellular senescence and mitochondrial dysfunction have both been defined as classical hallmarks of the ageing process. Here, we review the intricate relationship between the two. In the context of ageing, it is now well regarded that cellular senescence is a key driver in both ageing and the onset of a number of age‐related pathologies. Emerging evidence has pinpointed mitochondria as one of the key modulators in the development of the senescence phenotype, particularly the pro‐inflammatory senescence associated secretory phenotype (SASP). This review focuses on the contribution of homeostatic mechanisms, as well as of reactive oxygen species and mitochondrial metabolites in the senescence programme. Furthermore, we discuss emerging pathways and mitochondrial‐mediated mechanisms that may be influencing the SASP and, subsequently, explore how these may be exploited to open up new therapeutic avenues.
Alcohol Abstinence Does Not Fully Reverse Abnormalities of Mucosal-Associated Invariant T Cells in the Blood of Patients With Alcoholic Hepatitis
Li, Wei , Lin, Edward L. , Liangpunsakul, Suthat , Chalasani, Sai, Rane, Sushmita, Puri, Puneet , Kamath, Patrick S. , Shah, Vijay H. , Radaeva, Svetlana , Crabb, David W. , Chalasani, Naga , Yu, Qigui , Li, Wei , Li, Wei , Lin, Edward L., Lan, Jie , Sanyal, Arun J.

Mayo Clinic

Clinical and Translational Gastroenterology | June 18, 2019 | Volume: 10 | Issue: 6 | Pages: e00052

10.14309/ctg.0000000000000052 | PMID 31211759 Get It

OBJECTIVES: Alcoholic hepatitis (AH) develops in approximately 30% of chronic heavy drinkers. The immune system of patients with AH is hyperactivated, yet ineffective against infectious diseases. Mucosal-associated invariant T (MAIT) cells are innate-like lymphocytes that are highly enriched in liver, mucosa, and peripheral blood and contribute to antimicrobial immunity. We aimed to determine whether MAIT cells were dysregulated in heavy drinkers with and without AH and the effects of alcohol abstinence on MAIT cell recovery. METHODS: MR1 tetramers loaded with a potent MAIT cell ligand 5-(2-oxopropylideneamino)-6-d-ribitylaminouracil were used in multiparameter flow cytometry to analyze peripheral blood MAIT cells in 59 healthy controls (HC), 56 patients with AH, and 45 heavy drinkers without overt liver disease (HDC) at baseline and 6- and 12-month follow-ups. Multiplex immunoassays were used to quantify plasma levels of cytokines related to MAIT cell activation. Kinetic Turbidimetric Limulus Amebocyte Lysate Assay and ELISA were performed to measure circulating levels of 2 surrogate markers for bacterial translocation (lipopolysaccharide and CD14), respectively. RESULTS: At baseline, patients with AH had a significantly lower frequency of MAIT cells than HDC and HC. HDC also had less MAIT cells than HC (median 0.16% in AH, 0.56% in HDC, and 1.25% in HC). Further, the residual MAIT cells in patients with AH expressed higher levels of activation markers (CD69, CD38, and human leukocyte antigen [HLA]-DR), the effector molecule granzyme B, and the immune exhaustion molecule PD-1. Plasma levels of lipopolysaccharide and CD14 and several cytokines related to MAIT cell activation were elevated in patients with AH (interferon [IFN]-α, interleukin [IL]-7, IL-15, IL-17, IL-18, IL-23, IFN-γ, and tumor necrosis factor α). Decreased MAIT cell frequency and upregulated CD38, CD69, and HLA-DR correlated negatively and positively, respectively, with aspartate aminotransferase level. MAIT cell frequency negatively correlated with IL-18. HLA-DR and CD38 levels correlated with several cytokines. At follow-ups, abstinent patients with AH had increased MAIT cell frequency and decreased MAIT cell activation. However, MAIT cell frequency was not fully normalized in patients with AH (median 0.31%). DISCUSSION: We showed that HDC had a reduction of blood MAIT cells despite showing little evidence of immune activation, whereas patients with AH had a severe depletion of blood MAIT cells and the residual cells were highly activated. Alcohol abstinence partially reversed those abnormalities.
Outcomes of haploidentical vs matched sibling transplantation for acute myeloid leukemia in first complete remission
Rashidi, Armin , Hamadani, Mehdi , Zhang, Mei-Jie , Wang, Hai-Lin, Abdel‐Azim, Hisham , Aljurf, Mahmoud , Assal, Amer , Bashey, Asad, Beitinjaneh, Amer , Bejanyan, Nelli , Bolaños‐Meade, Javier , Byrne, Michael , Cahn, Jean‐Yves, Cairo, Mitchell S. , Ciurea, Stefan O. , Copelan, Edward A. , Daly, Andrew , Diaz, Miguel-Angel, Farhadfar, Nosha , Ganguly, Siddhartha , Hahn, Theresa , Hashmi, Shahrukh K. , Hildebrandt, Gerhard , Holland, H. Kent, Hossain, Nasheed , Kanakry, Christopher G. , Kharfan‐Dabaja, Mohamed A. , Khera, Nandita , Martino, Rodrigo , Munker, Reinhold , Murthy, Hemant S. , Nakamura, Ryotaro , Nathan, Sunita , Palmisiano, Neil , Patel, Sagar S. , Pidala, Joseph, Olin, Rebecca L. , Olsson, Richard F. , Ringdén, Olle , Rizzieri, David A. , Rowe, Jacob M. , Savoie, Mary Lynn , Seo, Sachiko , Shaffer, Brian C. , Singh, Anurag K. , Solh, Melhem , Stockerl‐Goldstein, Keith , Verdonck, Leo F. , Wagner, John L. , Waller, Edmund K. , Litzow, Mark R. , Weisdorf, Dan, Saber, Wael , Weisdorf, Daniel J. , Wagner, John E. , Gale, Robert P , Hashmi, Shahrukh K , Hildebrandt, Gerhard C , Kharfan-Dabaja, Mohamed A., McGuirk, Joseph , Murthy, Hemant S , Nishihori, Taiga , Patel, Sagar , Olsson, Richard F , Ringden, Olov , Savoie, Mary Lynn , Wagner, John , Waller, Edmund K , Sandmaier, Brenda M , Litzow, Mark R. , Weisdorf, Dan , Hamadani, Mehdi , Assal, Amer , Martino, Rodrigo , Zhang, Mei‐Jie , Bajel, Ashish R. , Battiwalla, Minoo , Bhatt, Vijaya Raj , Cahn, Jean‐Yves , Cutler, Corey S. , Gale, Robert Peter , Grunwald, Michael R. , Koç, Yener , Lazarus, Hillard M. , Lee, Jong Wook , Maertens, Johan A. , McGuirk, Joseph P. , Nishihori, Taiga , Oran, Betül , Schultz, Kirk R. , Lima, Marcos de , Romee, Rizwan , Rashidi, Armin , Stockerl-Goldstein, Keith

Mayo Clinic

Blood Advances | June 14, 2019 | Volume: 3 | Issue: 12 | Pages: 1826-1836

10.1182/bloodadvances.2019000050 | PMID 31201170 Get It

Abstract HLA-haploidentical hematopoietic cell transplantation (Haplo-HCT) using posttransplantation cyclophosphamide (PT-Cy) has improved donor availability. However, a matched sibling donor (MSD) is still considered the optimal donor. Using the Center for International Blood and Marrow Transplant Research database, we compared outcomes after Haplo-HCT vs MSD in patients with acute myeloid leukemia (AML) in first complete remission (CR1). Data from 1205 adult CR1 AML patients (2008-2015) were analyzed. A total of 336 patients underwent PT-Cy–based Haplo-HCT and 869 underwent MSD using calcineurin inhibitor–based graft-versus-host disease (GVHD) prophylaxis. The Haplo-HCT group included more reduced-intensity conditioning (65% vs 30%) and bone marrow grafts (62% vs 7%), consistent with current practice. In multivariable analysis, Haplo-HCT and MSD groups were not different with regard to overall survival (P = .15), leukemia-free survival (P = .50), nonrelapse mortality (P = .16), relapse (P = .90), or grade II-IV acute GVHD (P = .98). However, the Haplo-HCT group had a significantly lower rate of chronic GVHD (hazard ratio, 0.38; 95% confidence interval, 0.30-0.48; P < .001). Results of subgroup analyses by conditioning intensity and graft source suggested that the reduced incidence of chronic GVHD in Haplo-HCT is not limited to a specific graft source or conditioning intensity. Center effect and minimal residual disease–donor type interaction were not predictors of outcome. Our results indicate a lower rate of chronic GVHD after PT-Cy–based Haplo-HCT vs MSD using calcineurin inhibitor–based GVHD prophylaxis, but similar other outcomes, in patients with AML in CR1. Haplo-HCT is a viable alternative to MSD in these patients.
Biologic Significance of Magnetic Resonance Imaging Invisibility in Localized Prostate Cancer
Salami, Simpa S. , Kaplan, Jeremy , Nallandhighal, Srinivas , Takhar, Mandeep, Tosoian, Jeffrey J. , Lee, Matthew , Yoon, Junhee, Plouffe, Komal , Kaffenberger, Samuel D. , Schaeffer, Edward M. , Karnes, R. Jeffrey , George, Arvin K. , Montgomery, Jeffrey S., You, Sungyong , Tomlins, Scott A. , Curci, Nicole E. , Kim, Hyung L. , Spratt, Daniel E. , Palapattu, Ganesh S. , Spratt, Daniel E , Kim, Hyung L , Salami, Simpa S , Hovelson, Daniel H. , Lotan, Tamara Levin , Morgan, Todd M. , Davenport, Matthew S. , Udager, Aaron M , Lee, Matthew S

Mayo Clinic

JCO Precision Oncology | June 12, 2019 | Volume: No volume available | Issue: 3 | Pages: 1-12

10.1200/po.19.00054 | PMID 32914029 Get It

PURPOSE Multiparametric magnetic resonance imaging (mpMRI) is used widely for prostate cancer (PCa) evaluation. Approximately 35% of aggressive tumors, however, are not visible on mpMRI. We sought to identify the molecular alterations associated with mpMRI-invisible tumors and determine whether mpMRI visibility is associated with PCa prognosis. METHODS Discovery and validation cohorts included patients who underwent mpMRI before radical prostatectomy and were found to harbor both mpMRI-visible (Prostate Imaging and Reporting Data System 3 to 5) and -invisible (Prostate Imaging and Reporting Data System 1 or 2) foci on surgical pathology. Next-generation sequencing was performed to determine differential gene expression between mpMRI-visible and -invisible foci. A genetic signature for tumor mpMRI visibility was derived in the discovery cohort and assessed in an independent validation cohort. Its association with long-term oncologic outcomes was evaluated in a separate testing cohort. RESULTS The discovery cohort included 10 patients with 26 distinct PCa foci on surgical pathology, of which 12 (46%) were visible and 14 (54%) were invisible on preoperative mpMRI. Next-generation sequencing detected prioritized genetic mutations in 14 (54%) tumor foci (n = 8 mpMRI visible, n = 6 mpMRI invisible). A nine-gene signature (composed largely of cell organization/structure genes) associated with mpMRI visibility was derived (area under the curve = 0.89), and the signature predicted MRI visibility with 75% sensitivity and 100% specificity (area under the curve = 0.88) in the validation cohort. In the testing cohort (n = 375, median follow-up 8 years) there was no significant difference in biochemical recurrence, distant metastasis, or cancer-specific mortality in patients with predicted mpMRI-visible versus -invisible tumors (all P > .05). CONCLUSION Compared with mpMRI-invisible disease, mpMRI-visible tumors are associated with underexpression of cellular organization genes. mpMRI visibility does not seem to be predictive of long-term cancer outcomes, highlighting the need for biopsy strategies that detect mpMRI-invisible tumors.